TY - JOUR
T1 - MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
AU - Peeters, Marlies J W
AU - Dulkeviciute, Donata
AU - Draghi, Arianna
AU - Ritter, Cathrin
AU - Rahbech, Anne
AU - Skadborg, Signe K
AU - Seremet, Tina
AU - Carnaz Simões, Ana Micaela
AU - Martinenaite, Evelina
AU - Halldórsdóttir, Hólmfridur R
AU - Andersen, Mads Hald
AU - Olofsson, Gitte Holmen
AU - Svane, Inge Marie
AU - Rasmussen, Lene Juel
AU - Met, Özcan
AU - Becker, Jürgen C
AU - Donia, Marco
AU - Desler, Claus
AU - Thor Straten, Per
N1 - ©2019 American Association for Cancer Research.
PY - 2019/9
Y1 - 2019/9
N2 - The TAM family of receptor tyrosine kinases (TYRO3, AXL, and MERTK) is known to be expressed on antigen-presenting cells and function as oncogenic drivers and as inhibitors of inflammatory responses. Both human and mouse CD8+ T cells are thought to be negative for TAM receptor expression. In this study, we show that T-cell receptor (TCR)-activated human primary CD8+ T cells expressed MERTK and the ligand PROS1 from day 2 postactivation. PROS1-mediated MERTK signaling served as a late costimulatory signal, increasing proliferation and secretion of effector and memory-associated cytokines. Knockdown and inhibition studies confirmed that this costimulatory effect was mediated through MERTK. Transcriptomic and metabolic analyses of PROS1-blocked CD8+ T cells demonstrated a role of the PROS1-MERTK axis in differentiation of memory CD8+ T cells. Finally, using tumor-infiltrating lymphocytes (TIL) from melanoma patients, we show that MERTK signaling on T cells improved TIL expansion and TIL-mediated autologous cancer cell killing. We conclude that MERTK serves as a late costimulatory signal for CD8+ T cells. Identification of this costimulatory function of MERTK on human CD8+ T cells suggests caution in the development of MERTK inhibitors for hematologic or solid cancer treatment.
AB - The TAM family of receptor tyrosine kinases (TYRO3, AXL, and MERTK) is known to be expressed on antigen-presenting cells and function as oncogenic drivers and as inhibitors of inflammatory responses. Both human and mouse CD8+ T cells are thought to be negative for TAM receptor expression. In this study, we show that T-cell receptor (TCR)-activated human primary CD8+ T cells expressed MERTK and the ligand PROS1 from day 2 postactivation. PROS1-mediated MERTK signaling served as a late costimulatory signal, increasing proliferation and secretion of effector and memory-associated cytokines. Knockdown and inhibition studies confirmed that this costimulatory effect was mediated through MERTK. Transcriptomic and metabolic analyses of PROS1-blocked CD8+ T cells demonstrated a role of the PROS1-MERTK axis in differentiation of memory CD8+ T cells. Finally, using tumor-infiltrating lymphocytes (TIL) from melanoma patients, we show that MERTK signaling on T cells improved TIL expansion and TIL-mediated autologous cancer cell killing. We conclude that MERTK serves as a late costimulatory signal for CD8+ T cells. Identification of this costimulatory function of MERTK on human CD8+ T cells suggests caution in the development of MERTK inhibitors for hematologic or solid cancer treatment.
UR - http://www.scopus.com/inward/record.url?scp=85071784139&partnerID=8YFLogxK
U2 - 10.1158/2326-6066.CIR-18-0841
DO - 10.1158/2326-6066.CIR-18-0841
M3 - Journal article
C2 - 31266785
SN - 2326-6066
VL - 7
SP - 1472
EP - 1484
JO - Cancer immunology research
JF - Cancer immunology research
IS - 9
ER -